Search

Search Constraints

You searched for: Author/Creator Ho, A D

Search Results

6. Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program. Issue 2 (10th January 2023)